Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthma

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 8, 2015, Pages

  Anderson, Debbie E ^a   Kew, Kayleigh M ^b   Boyter, Anne C ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACLIDINIUM BROMIDE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; GLYCOPYRRONIUM; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; RESPIMAT; TIOTROPIUM BROMIDE; ANTIASTHMATIC AGENT;

ADD ON THERAPY; ADULT; ASTHMA; ASTHMA CONTROL QUESTIONNAIRE; ASTHMA QUALITY OF LIFE QUESTIONNAIRE; DISEASE CONTROL; DISEASE DURATION; DISEASE EXACERBATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EVIDENCE BASED MEDICINE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HOSPITAL ADMISSION; HUMAN; LOW DRUG DOSE; LUNG FUNCTION; OUTCOME ASSESSMENT; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; COMBINATION DRUG THERAPY; DISEASE COURSE; FEMALE; INHALATIONAL DRUG ADMINISTRATION; MALE; META ANALYSIS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MUSCARINIC ANTAGONISTS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84991247096     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD011397.pub2     Document Type: Review

References (68)

1. Bateman ED, Kornmann O, Schmidt P, Pivovarova A, Engel M, Fabbri LM. Tiotropium is non inferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. Journal of Allergy and Clinical Immunology 2011;128(2):315-22.
2. Dahl R, Bateman ED, Casale T, Pizzichini E, Vandewalker M, Virchow JC, et al. Once-daily tiotropium Respimat as add-on to at least medium-to high-dose ICS, with or without LABA, improves lung function in patients with symptomatic asthma, independent of allergic status. 33rd Congress of the European Academy of Allergy and Clinical Immunology, Copenhagen. 2014:515.
3. NCT00350207. A 16-week randomised, placebo-controlled, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of tiotropium inhalation solution delivered by the Respimat inhaler (2 actuations of 2.5 mcg once daily) with that of salmeterol from the hydrofluoroalkane metered dose inhaler (2 actuations of 25 mcg twice daily) in moderate persistent asthma patients with the B16-Arg/Arg genotype. http://www.clinicaltrials.gov/show/NCT00350207 (accessed 19 December 2014).
4. Kerstjens HAM, Casale TB, Bleecker ER, Meltzer EO, Pizzichini E, Schmidt O, et al. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. Lancet Respiratory Medicine 2015 Feb 12 [Epub ahead of print].
5. ® Inhaler (2.5 and 5 mcg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 mcg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma. http://www.clinicaltrials.gov/show/NCT01172808 (accessed 19 December 2014).
6. Casale T, Bleecker E, Meltzer E, Pizzichini E, Schmidt O, Bateman E, et al. Phase III trials to investigate tiotropium as add-on therapy to inhaled corticosteroids for patients with symptomatic asthma: trial design and planned statistical analyses. Allergy 2013;68:377.
7. Casale TB, Bateman ED, Dahl R, Pizzichini E, Vandewalker ML, Virchow JC, et al. Tiotropium Respimat add-on therapy reduces airflow obstruction in patients with symptomatic moderate asthma, independent of Th2 inflammatory status. Journal of Allergy and Clinical Immunology 2014;133(2 Suppl):AB5.
8. Kerstjens HAM, Casale TB, Bleecker ER, Meltzer EO, Pizzichini E, Schmidt O, et al. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. Lancet Respiratory Medicine 2015 Feb 12 [Epub ahead of print].
9. ® Inhaler (2.5 and 5 mcg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 mcg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma. http://www.clinicaltrials.gov/show/NCT01172821 (accessed 19 December 2014).
10. ® inhaler (2.5 mcg and 5 mcg once daily) compared to placebo over 12 weeks in mild persistent asthma. http://www.clinicaltrials.gov/show/NCT01316380 (accessed 19 December 2014).
11. Paggiaro P, Engel M, Tudoric N, Forstner B, Radeczky E, Zubek V, et al. Phase III trial of tiotropium as add-on therapy to low-dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: design and planned analyses [Abstract]. European Respiratory Journal 2013;42(Suppl 57):877s [P4133].
12. Paggiaro P, Halpin DMG, Buhl R, Engel M, Zubek V, Blahova Z, et al. Tiotropium Respimat add-on to inhaled corticosteroids improves lung function in patients with symptomatic mild asthma: results from a phase III trial. Journal of Allergy and Clinical Immunology 2014;133(2 Suppl):AB4.
13. NCT01340209. A phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate safety and efficacy of tiotropium inhalation solution delivered via Respimat inhaler (2.5 and 5 g once daily) compared with placebo over 52 weeks in patients with moderate to severe persistent asthma. http://www.clinicaltrials.gov/show/NCT01340209 (accessed 19 December 2014).
14. Ohta K, Ichinose M, Tohda Y, Engel M, Moroni-Zentgraf P, Kunimitsu S, et al. Long-term once daily tiotropium Respimat is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: a randomised, placebo-controlled study. PLoS ONE 2015;10(4):e0124109.
15. Chest Research Foundation. A clinical trial comparing bronchodilator effects of two drugs, tiotropium bromide and formoterol fumarate, each over 24 hours in subjects with asthma. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2008/091/000306 (accessed 19 December 2014).
16. Ilango Dr K. A clinical trial to study the effects of few anti asthmatic drug combinations on asthma patients. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2012/08/002915 (accessed 19 December 2014).
17. Boehringer Ingelheim Pharma GmbH, Co. KG. The effect of tiotropium-bromide on deep inspiration-induced bronchodilation and airway responsiveness in asthma -Tiotropium-bromide and lung mechanics. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-003385-34-NL (accessed 19 December 2014).
18. Saitama Medical University. Randomized clinical study with tiotropium and formoterol/budesonide in COPD with asthma. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000003618 (accessed 19 December 2014).
19. EACC (Ehime Asthma COPD Conference). Add-on therapy for COPD receiving inhaled bronchodilators. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000005459 (accessed 19 December 2014).
20. Fukuoka National Hospital. Study for effects of tiotropium on smokers and non-smokers with bronchial asthma. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000010352 (accessed 19 December 2014).
21. Corren J, Frew A, Engel M, Schmidt H, Moroni-Zentgraf P, Kerstjens HAM. Tiotropium as add-on therapy to ICS+LABA in patients with symptomatic severe asthma: spirometric assessment over 24 hours [Abstract]. American College of Chest Physicians 2013;144:91A.
22. Kerstjens HAM, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, et al. Tiotropium in asthma poorly controlled with standard combination therapy. New England Journal of Medicine 2012;367(13):1198-207.
23. Vandewalker ML, Engel M, Schmidt H, Siebold W, Moroni-Zentgraf P, Kerstjens H, et al. Efficacy of tiotropium in patients with asthma in relation to allergic status [Abstract]. Journal of Allergy and Clinical Immunology 2013;131(2 Suppl 1):AB1.
24. NCT00546234. Assessing treatment options for smokers with asthma. www.clinicaltrials.gov/show/NCT00546234 (accessed 4 March 2015).
25. National Jewish Health. Examining the link between obesity, inflammation, and response to asthma medications. https://clinicaltrials.gov/show/NCT00557180 (accessed 19 December 2014).
26. NCT00557700. Study to investigate the effect of inhaled tiotropium bromide on neurokinin-A induced bronchoconstriction in patients with mild-to-moderate asthma. www.clinicaltrials.gov/show/NCT00557700 (accessed 4 March 2015).
27. NCT00706446. Genotype stratified treatment with anticholinergic vs. beta-agonist (long-acting) and exacerbations (GABLE). www.clinicaltrials.gov/show/NCT00706446 (accessed 4 March 2015).
28. ® inhaler (5 mcg/day) over 48 weeks as add-on controller therapy on top of usual care in patients with severe persistent asthma. www.clinicaltrials.gov/show/NCT00772538 (accessed 4 March 2015).
29. ® inhaler (5 mcg/day) over 48 weeks as add-on controller therapy on top of usual care in patients with severe persistent asthma. www.clinicaltrials.gov/show/NCT00776984 (accessed 4 March 2015).
30. NCT01290874. Blacks and exacerbations on LABA vs. tiotropium (BELT). www.clinicaltrials.gov/show/NCT01290874 (accessed 4 March 2015).
31. NCT01573624. A multi-center, randomized, double-blind, dose-ranging study to evaluate GSK573719 in combination with fluticasone furoate, fluticasone furoate alone, and an active control of fluticasone furoate/vilanterol combination in subjects with asthma. www.clinicaltrials.gov/show/NCT01573624 (accessed 4 March 2015).
32. NCT01641692. A multi-national, randomized, double-blind, placebo-controlled, 3-period crossover study with GSK 573719 as monotherapy in adult subjects with asthma. www.clinicaltrials.gov/show/NCT01641692 (accessed 4 March 2015).
33. NCT01696214. SAPS: Smoking Asthmatics Pilot Study. www.clinicaltrials.gov/show/NCT01696214 (accessed 4 March 2015).
34. NCT02066298. Steroids in eosinophil negative asthma. www.clinicaltrials.gov/show/NCT02066298 (accessed 4 March 2015).
35. NCT02127697. A randomized, double-blind, parallel group, 52-week study evaluating the efficacy, safety and tolerability of NVA237 in patients with poorly controlled asthma. www.clinicaltrials.gov/show/NCT02127697 (accessed 4 March 2015).
36. Vogelberg C, Engel M, Moroni-Zentgraf P, Leonaviciute-Klimantaviciene M, Sigmund R, Downie J, et al. Once-daily tiotropium in adolescents with symptomatic asthma despite inhaled corticosteroid treatment: a dose-ranging study [Abstract]. Clinical and Translational Allergy 2014;4(Suppl 1):2 [O5].
37. Asthma UK. Asthma Facts and FAQs. http://www.asthma.org.uk/asthma-facts-and-statistics (accessed 20 August 2014).
38. Barnes PJ, Jonsson B, Klim JB. The costs of asthma. European Respiratory Journal 1996;9:636-42. [DOI: 10.1183/09031936.96.09040636]
39. ® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma. Respiratory Research 2014;15:61. [DOI: 10.1186/1465-9921-15-61]
40. Befekadu E, Onofrei C, Colice G. Tiotropium in asthma: a systematic review. Journal of Asthma and Allergy 2014;7:11-21. [DOI: 10.2147/JAA.S38841]
41. Brozek J, Oxman A, Schünemann H. GRADEpro. 3.2 for Windows. GRADE Working Group, 2008.
42. British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN). British Guideline on the Management of Asthma. https://www.brit-thoracic.org.uk/guidelines-and-quality-standards/ (accessed 29 July 2014).
43. Centers for Disease Control and Prevention. Asthma Surveillance Data. http://www.cdc.gov/asthma/ (accessed 20 August 2014).
44. Chauhan BF, Chartrand C, Ducharme FM. Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults. Cochrane Database of Systematic Reviews 2013, Issue 2. [DOI: 10.1002/14651858.CD009611.pub3]
45. 2-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD003137.pub5]
46. The Alfred Hospital, Monash University, National ICT Australia and the University of London. Covidence. Prahran VIC: Alfred Health, 2013.
47. Department of Health. An outcomes strategy for COPD and asthma: NHS companion document. https://www.gov.uk/government/publications/an-outcomes-strategy-for-copd-and-asthma-nhs-companion-document (accessed 20 August 2014).
48. Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database of Systematic Reviews 2010, Issue 4. [DOI: 10.1002/14651858.CD005533.pub2]
49. Boehringer Ingelheim Limited. Summary of product characteristics: Spiriva 18 microgram inhalation powder, hard capsule. https://www.medicines.org.uk/emc/medicine/10039 (accessed 20 August 2014).
50. Boehringer Ingelheim Limited. Summary of product characteristics: Spiriva Respimat 2.5 micrograms solution for inhalation. https://www.medicines.org.uk/emc/medicine/20134 (accessed 20 August 2014).
51. Electronic Medicines Compendium. License extension 19th September 2014: Spiriva Respimat 2.5 micrograms solution for inhalation. https://www.medicines.org.uk/emc/history/20134 (accessed 24 October 2014).
52. Almirall Limited. Sumary of product characteristics: Eklira Genuair 322 micrograms inhalation powder. https://www.medicines.org.uk/emc/medicine/27001 (accessed 20 August 2014).
53. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2014. http://www.ginasthma.org/local/uploads/files/GINA_Report_2014_Aug12.pdf (accessed 28 July 2014).
54. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention -Revised 2014. http://www.ginasthma.org/local/uploads/files/GINA_Report_2014_Aug12.pdf (accessed 20 October 2014). [http://www.ginasthma.org/local/uploads/files/GINA_Report_2014_Aug12.pdf]
55. International Union Against Tuberculosis and Lung Disease. The Global Asthma Report 2011. http://www.theunion.org/what-we-do/publications/english/global_asthma_report2011.pdf (accessed 4 August 2014).
56. Masoli M, Fabian D, Holt S, Beasley R. Global Burden of Asthma. http://www.ginasthma.org/local/uploads/files/GINABurdenReport_1.pdf (accessed 16 September 2014).
57. Gosens R, Zaagsma J, Meurs H, Halayko AJ. Muscarinic receptor signalling in the pathophysiology of asthma and COPD. Respiratory Research 2006;7(1):73. [DOI: 10.1186/1465-9921-7-73]
58. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
59. Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD009285.pub3]
60. Kew KM, Evans DJW, Anderson DE, Boyter AC. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthma. Cochrane Database of Systematic Reviews 2015, Issue 6. [DOI: 10.1002/14651858.CD011438.pub2]
61. National Institute of Health and Care Excellence. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care CG101. http://www.nice.org.uk/guidance/CG101 (accessed 20 August 2014).
62. Peters S, Kunselman S, Icitovic N, Moore WC, Pascual R, Ameredes BT, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. New England Journal of Medicine 2010;363:1715-26. [DOI: 10.1056/NEJMoa1008770]
63. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
64. Rodrigo GJ, Castro-Rodriguez JA. What is the role of tiotropium in asthma?: a systematic review with meta-analysis. Chest 2015;147(2):388-96. [DOI: 10.1378/chest.14-1698]
65. Tian JW, Chen JW, Chen R, Chen X. Tiotropium versus placebo for inadequately controlled asthma: a meta-analysis. Respiratory Care 2014;59(5):654-66. [DOI: 10.4187/respcare.02703]
66. ® 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma. Respiratory Medicine 2014:[Epub ahead of print]. [DOI: 10.1016/j.rmed.2014.12.005]
67. World Health Organization. Global surveillance, prevention and control of chronic respiratory diseases: A comprehensive approach. Global Surveillance, Prevention and Control of Chronic Respiratory Diseases: A Comprehensive Approach. Geneva, Switzerland: World Health Organization, 2007.
68. Allison DE, Kew KM, Boyter AC. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS for adults with asthma. Cochrane Database of Systematic Reviews 2014, Issue 11. [DOI: 10.1002/14651858.CD011397]